<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Elicio Therapeutics Inc. — News on 6ix</title>
<link>https://6ix.com/company/elicio-therapeutics-inc</link>
<description>Latest news and press releases for Elicio Therapeutics Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 12 Mar 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/elicio-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683562d978dffbe2df0ef017.webp</url>
<title>Elicio Therapeutics Inc.</title>
<link>https://6ix.com/company/elicio-therapeutics-inc</link>
</image>
<item>
<title>Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates</title>
<link>https://6ix.com/company/elicio-therapeutics-inc/news/elicio-therapeutics-reports-full-year-2025-financial-results-and-provides-corporate-updates</link>
<guid isPermaLink="true">https://6ix.com/company/elicio-therapeutics-inc/news/elicio-therapeutics-reports-full-year-2025-financial-results-and-provides-corporate-updates</guid>
<pubDate>Thu, 12 Mar 2026 20:05:00 GMT</pubDate>
<description>Event-driven primary disease-free survival (“DFS”) analysis for Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma (“PDAC”) is anticipated in 1H 2026Fewer disease progressions and deaths than projected to date have been observed in the ongoing 2:1 randomized Phase 2 AMPLIFY-7P trial The Company remains blinded to the Phase 2 AMPLIFY-7P trial clinical efficacy outcomes.Projected cash runway into Q3 2026, beyond the anticipated AMPLIFY-7P Phase 2 DFS a</description>
</item>
<item>
<title>Elicio Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference</title>
<link>https://6ix.com/company/elicio-therapeutics-inc/news/elicio-therapeutics-to-present-at-the-td-cowen-46th-annual-health-care-conference</link>
<guid isPermaLink="true">https://6ix.com/company/elicio-therapeutics-inc/news/elicio-therapeutics-to-present-at-the-td-cowen-46th-annual-health-care-conference</guid>
<pubDate>Wed, 25 Feb 2026 13:00:00 GMT</pubDate>
<description>BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert Connelly, Chief Executive Officer, and Pete DeMuth, PhD, Chief Scientific Officer, will participate in the upcoming TD Cowen 46th Annual Health Care Conference, taking place March 2-4, 2026, in Boston, MA. TD Cowen 46th Annual Health Care Confere</description>
</item>
<item>
<title>Elicio Therapeutics Reports Inducement Grants</title>
<link>https://6ix.com/company/elicio-therapeutics-inc/news/elicio-therapeutics-reports-inducement-grants-130000994</link>
<guid isPermaLink="true">https://6ix.com/company/elicio-therapeutics-inc/news/elicio-therapeutics-reports-inducement-grants-130000994</guid>
<pubDate>Fri, 16 Jan 2026 13:00:00 GMT</pubDate>
<description>BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on January 15, 2026, Elicio granted an aggregate of 22,400 inducement stock options to two new employees, as an inducement material to each individual entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement</description>
</item>
<item>
<title>Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial</title>
<link>https://6ix.com/company/elicio-therapeutics-inc/news/elicio-therapeutics-reports-antigen-spreading-130000653</link>
<guid isPermaLink="true">https://6ix.com/company/elicio-therapeutics-inc/news/elicio-therapeutics-reports-antigen-spreading-130000653</guid>
<pubDate>Thu, 11 Dec 2025 13:00:00 GMT</pubDate>
<description>Antigen spreading was evaluated in a subset of Phase 2 patients to assess the ability of ELI-002 7P to broaden immune responses to personalized tumor neoantigens not present in the targeted immunotherapy87% (13/15) of evaluated patients demonstrated induction of T cell responses to tumor neoantigens beyond mKRAS following ELI-002 7P therapyThe induction of non-mKRAS antigen-specific T cell responses supports the potential for ELI-002 7P to generate a broader, more adaptable, and personalized ant</description>
</item>
<item>
<title>Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer</title>
<link>https://6ix.com/company/elicio-therapeutics-inc/news/elicio-therapeutics-appoints-veteran-cmc-130000096</link>
<guid isPermaLink="true">https://6ix.com/company/elicio-therapeutics-inc/news/elicio-therapeutics-appoints-veteran-cmc-130000096</guid>
<pubDate>Wed, 19 Nov 2025 13:00:00 GMT</pubDate>
<description>Strategic Hire Strengthens Late Phase and Commercial Readiness as Elicio Advances Lymph Node-Targeted Immunotherapy PipelineBOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Marc J. Wolfgang, M.S. as Chief Technology Officer (“CTO”). Mr. Wolfgang brings more than 30 years of biopharmaceut</description>
</item>
<item>
<title>Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates</title>
<link>https://6ix.com/company/elicio-therapeutics-inc/news/elicio-therapeutics-reports-third-quarter-210100176</link>
<guid isPermaLink="true">https://6ix.com/company/elicio-therapeutics-inc/news/elicio-therapeutics-reports-third-quarter-210100176</guid>
<pubDate>Thu, 13 Nov 2025 21:01:00 GMT</pubDate>
<description>In the ongoing Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma (“PDAC”), fewer disease progressions and deaths than projected have been observed as of November 6, 2025. Based on 2:1 randomization with twice as many patients in the ELI-002 7P treatment arm compared to the observation arm, Elicio believes the lower-than-projected number of disease progressions and deaths may reflect a favorable impact on disease-free survival (“DFS”); event-driven p</description>
</item>
<item>
<title>Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC</title>
<link>https://6ix.com/company/elicio-therapeutics-inc/news/elicio-therapeutics-reports-robust-cytolytic-140000381</link>
<guid isPermaLink="true">https://6ix.com/company/elicio-therapeutics-inc/news/elicio-therapeutics-reports-robust-cytolytic-140000381</guid>
<pubDate>Fri, 07 Nov 2025 14:00:00 GMT</pubDate>
<description>SITC abstracts highlight updated immunogenicity results from the Phase 2 AMPLIFY-7P trial of ELI-002 7P and preclinical data on the use of intratumoral ELI-004 (AMP-CpG) for solid tumor immunotherapyELI-002 7P induced mKRAS-specific T cell responses in 99% of evaluable patients (89/90), demonstrating potent and consistent immune activationRobust immune responses were elicited across all seven mKRAS antigens, with >80% response rate to each individual KRAS mutation and 88% of patients generating</description>
</item>
<item>
<title>Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial</title>
<link>https://6ix.com/company/elicio-therapeutics-inc/news/elicio-therapeutics-reports-robust-t-120000441</link>
<guid isPermaLink="true">https://6ix.com/company/elicio-therapeutics-inc/news/elicio-therapeutics-reports-robust-t-120000441</guid>
<pubDate>Mon, 27 Oct 2025 12:00:00 GMT</pubDate>
<description>ELI-002 7P demonstrated robust mKRAS-specific T cell responses across a broad range of HLA types, highlighting its potential for use among a diverse patient populationPatients treated with ELI-002 7P represented a diverse HLA repertoire including 1,132 unique types identified among 1,398 total HLA backgrounds in assessed patients99% (88/89) of patients assessed for HLA background induced mKRAS-specific T cell responses after treatment with ELI-002 7PInduction of mKRAS-specific T cell responses s</description>
</item>
<item>
<title>Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma</title>
<link>https://6ix.com/company/elicio-therapeutics-inc/news/elicio-therapeutics-announces-investigator-initiated-120000776</link>
<guid isPermaLink="true">https://6ix.com/company/elicio-therapeutics-inc/news/elicio-therapeutics-announces-investigator-initiated-120000776</guid>
<pubDate>Mon, 29 Sep 2025 12:00:00 GMT</pubDate>
<description>Study will evaluate ELI-002 7P in combination with chemotherapy and a checkpoint inhibitor (“CPI”) in the neoadjuvant settingTrial is anticipated to begin enrolling in H1’2026 BOSTON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the planned initiation of an investigator-initiated Phase 1 neoadjuvant study of</description>
</item>
<item>
<title>Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial</title>
<link>https://6ix.com/company/elicio-therapeutics-inc/news/elicio-therapeutics-reports-eli-002-120000559</link>
<guid isPermaLink="true">https://6ix.com/company/elicio-therapeutics-inc/news/elicio-therapeutics-reports-eli-002-120000559</guid>
<pubDate>Wed, 17 Sep 2025 12:00:00 GMT</pubDate>
<description>ELI-002 induced mKRAS-specific T cell responses in 99% of evaluable patients (89 of 90) who were treated with the investigational vaccine immunotherapyRobust mKRAS-specific T cell responses were observed with an average of 145.3x increase over baseline (median 44.3x; range 2.13-1310x), consistent with prior ELI-002 Phase 1 trial resultsT cell responses included both mKRAS-specific CD4 and CD8 T cells in 85% of patients BOSTON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq:</description>
</item>
<item>
<title>Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients</title>
<link>https://6ix.com/company/elicio-therapeutics-inc/news/elicio-therapeutics-announces-publication-eli-120000688</link>
<guid isPermaLink="true">https://6ix.com/company/elicio-therapeutics-inc/news/elicio-therapeutics-announces-publication-eli-120000688</guid>
<pubDate>Tue, 12 Aug 2025 12:00:00 GMT</pubDate>
<description>At extended median follow-up of 19.7 months, median overall survival (“OS”) increased from 16.33 to 28.94 months Clinical efficacy correlated with the magnitude of T cell responses specific to mutant-KRAS (“mKRAS”) induced by ELI-00277% reduction in the risk of death and 88% reduction in the risk of relapse, associated with T cell responses above the threshold for anti-tumor efficacyELI-002 induced both CD4+ and CD8+ mKRAS-specific T cell responses in most patients, and evidence of antigen-sprea</description>
</item>
<item>
<title>Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates</title>
<link>https://6ix.com/company/elicio-therapeutics-inc/news/elicio-therapeutics-reports-second-quarter-203000757</link>
<guid isPermaLink="true">https://6ix.com/company/elicio-therapeutics-inc/news/elicio-therapeutics-reports-second-quarter-203000757</guid>
<pubDate>Thu, 07 Aug 2025 20:30:00 GMT</pubDate>
<description>Recent positive recommendation by the Independent Data Monitoring Committee (“IDMC”) to continue ELI-002 7P randomized Phase 2 study in pancreatic cancer without modifications to final analysis Event-driven final analysis focused on disease-free survival (“DFS”) expected in Q4 2025 Secured $10 million financing in Q2 2025; Current cash position expected to support operations beyond anticipated AMPLIFY-7P Phase 2 final analysis BOSTON, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (</description>
</item>
<item>
<title>Elicio Therapeutics Announces Positive Recommendation by IDMC to Continue ELI-002 7P Randomized Phase 2 Study in Pancreatic Cancer Without Modifications to Final Analysis</title>
<link>https://6ix.com/company/elicio-therapeutics-inc/news/elicio-therapeutics-announces-positive-recommendation-110000785</link>
<guid isPermaLink="true">https://6ix.com/company/elicio-therapeutics-inc/news/elicio-therapeutics-announces-positive-recommendation-110000785</guid>
<pubDate>Tue, 05 Aug 2025 11:00:00 GMT</pubDate>
<description>The AMPLIFY-7P study of ELI-002 7P successfully passes event-driven interim analysis for efficacy, futility, and safety by the IDMC The Company views the IDMC’s positive recommendation as an indication that ELI-002 7P has shown preliminary signals of efficacy Final disease-free survival analysis is anticipated to occur in Q4 2025Elicio previously reached alignment with the FDA on key elements of the planned pivotal Phase 3 study designThe Company’s current cash runway extends into Q1 2026, past</description>
</item>
<item>
<title>Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer</title>
<link>https://6ix.com/company/elicio-therapeutics-inc/news/elicio-therapeutics-host-virtual-kol-120000851</link>
<guid isPermaLink="true">https://6ix.com/company/elicio-therapeutics-inc/news/elicio-therapeutics-host-virtual-kol-120000851</guid>
<pubDate>Tue, 17 Jun 2025 12:00:00 GMT</pubDate>
<description>BOSTON, June 17, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it will host a virtual key opinion leader (“KOL”) event on Wednesday, June 25, 2025 at 2:00 PM ET to discuss the significant unmet need and current treatment landscape for mutant-KRAS (“mKRAS”) driven pancreatic ductal adenocarcinoma (“PDAC”), one of th</description>
</item>
<item>
<title>Elicio Therapeutics Secures $10 Million in Financing</title>
<link>https://6ix.com/company/elicio-therapeutics-inc/news/elicio-therapeutics-secures-10-million-120000902</link>
<guid isPermaLink="true">https://6ix.com/company/elicio-therapeutics-inc/news/elicio-therapeutics-secures-10-million-120000902</guid>
<pubDate>Wed, 04 Jun 2025 12:00:00 GMT</pubDate>
<description>Funding expected to support operations into Q1 2026. Anticipated AMPLIFY-7P Phase 2 interim analysis expected in Q3 2025. BOSTON, June 04, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it has entered a $10 million senior secured promissory note (the “Note”) with existing investor, GKCC, LLC (“Note Holder” or “GKCC”</description>
</item>
<item>
<title>Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates</title>
<link>https://6ix.com/company/elicio-therapeutics-inc/news/elicio-therapeutics-reports-first-quarter-200500641</link>
<guid isPermaLink="true">https://6ix.com/company/elicio-therapeutics-inc/news/elicio-therapeutics-reports-first-quarter-200500641</guid>
<pubDate>Tue, 13 May 2025 20:05:00 GMT</pubDate>
<description>Interim analysis focused on disease-free survival (“DFS”) in randomized Phase 2 AMPLIFY-7P clinical trial expected in Q3 2025 Company has alignment with U.S. Food and Drug Administration (“FDA”) on key design elements of planned Phase 3 study of ELI-002 Current cash position expected to support operations beyond anticipated AMPLIFY-7P Phase 2 interim analysis BOSTON, May 13, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnolo</description>
</item>
<item>
<title>Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires</title>
<link>https://6ix.com/company/elicio-therapeutics-inc/news/elicio-therapeutics-reports-inducement-grant-200500942</link>
<guid isPermaLink="true">https://6ix.com/company/elicio-therapeutics-inc/news/elicio-therapeutics-reports-inducement-grant-200500942</guid>
<pubDate>Wed, 16 Apr 2025 20:05:00 GMT</pubDate>
<description>BOSTON, April 16, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on April 15, 2025, Elicio granted inducement awards to Elicio’s newly appointed Chief Strategy and Financial Officer, Preetam Shah, and two additional new employees, as an inducement material to Dr. Shah and such employees entering into employm</description>
</item>
<item>
<title>Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates</title>
<link>https://6ix.com/company/elicio-therapeutics-inc/news/elicio-therapeutics-reports-2024-financial-110000910</link>
<guid isPermaLink="true">https://6ix.com/company/elicio-therapeutics-inc/news/elicio-therapeutics-reports-2024-financial-110000910</guid>
<pubDate>Mon, 31 Mar 2025 11:00:00 GMT</pubDate>
<description>Completed enrollment of Phase 2 AMPLIFY-7P randomized study; disease-free survival (“DFS”) event-driven interim analysis expected in Q3 2025 Aligned with U.S. Food and Drug Administration (“FDA”) on key elements of planned ELI-002 Phase 3 study design, including dose, patient population and primary endpoint analysis Strengthened cash position to support operations beyond the anticipated AMPLIFY-7P Phase 2 interim analysis BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasd</description>
</item>
<item>
<title>Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer</title>
<link>https://6ix.com/company/elicio-therapeutics-inc/news/elicio-therapeutics-appoints-preetam-shah-110000590</link>
<guid isPermaLink="true">https://6ix.com/company/elicio-therapeutics-inc/news/elicio-therapeutics-appoints-preetam-shah-110000590</guid>
<pubDate>Mon, 24 Mar 2025 11:00:00 GMT</pubDate>
<description>BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer, effective as of the date hereof. Dr. Shah brings a wealth of leadership experience to Elicio after previously serving as chief financial officer, chief business of</description>
</item>
</channel>
</rss>